TLDR:
- Regeneron Ventures, seeded with $500 million by Regeneron, debuts in the venture investing arena.
- The fund will be independently managed by former Regeneron executives with a focus on innovative science and breakthrough technologies in healthcare, biopharmaceuticals, and health tech.
Article Summary:
Regeneron has entered the venture investing space with the launch of Regeneron Ventures, funded with $500 million by the pharma company over a five-year period. The venture capital fund will be managed independently by former Regeneron executives Dr. Jay S. Markowitz and Dr. Michael Aberman, with a focus on science, data, and breakthrough innovation in healthcare, biopharmaceuticals, and health tech.
The fund plans to invest in ground-breaking advancements across various therapeutic areas, technologies, and development stages. Despite a decline in VC investments in the biopharma sector last year, healthcare specialist private equity funds surged, indicating a shifting market trend in the industry. Regeneron Ventures aims to support the next generation of biotechs and drive advancements that push the boundaries of science and medicine, leveraging the expertise and lessons learned at Regeneron.
